Meta Platforms Inc. (NASDAQ:META) is among the best stocks you’ll wish you bought sooner. On December 4, Citi reiterated its ...

HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today presented new first-in-human data from ...

Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...

First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leuk ...

R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

Group International announced that it has presented an oral report featuring the latest results from a registrational ...

Incyte today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal ...

Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating ...

Income investing with dividends can reduce retirement risks vs. fixed withdrawals. Learn more about how to make your ...